Elevance Health Inc. ELV

NYSE · Healthcare · Medical - Healthcare Plans

$394.48

Close on Fri, 20 Nov 2026 · market value $85.2B

What the price is betting on

Below its record

At $394, the price assumes revenue shrinks about 13% a year for five years, from $202B to about $109B by FY2030. That is less than what analysts expect for the next two years and less than the company's own last three years.

The price assumes−13%
Analysts, next two years2.3%
Last 3 years6.1%

Revenue growth a year. The price figure comes from a reverse DCF at a 8% discount rate.

Track it and Parra checks each report against the path, and tells you when revenue falls behind it.

Own more than ELV? Check up to 5 of your stocks at once, free, no account.

0$100B$200B$300B$202B'22'23'24'25Sep '26'26'27'28'29'30What the price needsReportedAnalysts

Both sides

Three stories, three values

Bear

$671

Base

$733

Bull

$801

Today $394

  • Bear $671. Cash flow grows 0% a year for the next 5 years, slower than expected, then slows to long-run growth.
  • Base $733. Cash flow grows 2% a year for the next 5 years, as analysts expect, then slows to long-run growth.
  • Bull $801. Cash flow grows 4% a year for the next 5 years, faster than expected, then slows to long-run growth.

Stories set by rules from the company’s record.

Checkpoints

The revenue the price needs

  1. YearNeedsAnalysts expect
  2. FY2026$195B$200B, on the path
  3. FY2027$169B$205B, on the path
  4. FY2028$146B$213B, on the path
  5. FY2029$126B$217B, on the path
  6. FY2030$109B$238B, on the path

Each year's revenue at −13% growth from $202B in the 12 months to September 2026.

At a glance

Healthcare · Medical - Healthcare Plans · listed on NYSE

Revenue, FY2025
$199B
Growth, 3 years a year
6.1%
Cash margin
1.6%
Net debt
$23.7B
Shares, 3-year change
−8.6%
Dividend yield
1.8%

What other healthcare prices are betting on

Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.